Banner

AntiParkinson Drugs Global Market Report 2023 – By Drugs Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAOB) Inhibitors, CatecholOMethyltransferase (COMT)inhibitors, Anticholinergics, Other Drugs), By Route of Administration (Oral, Injection, Transdermal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : January 2023 | SKU CODE : r727 | Delivery Time: 2-3 business days | Format :


Anti-parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson's disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic's negative effects.

The main class of anti-Parkinson drugs is levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type b (MAO-b) inhibitors, catechol-o-methyltransferase (COMT)-inhibitors, anticholinergics, and other drugs. Catechol-O-methyltransferase (COMT) inhibitors are a class of drugs used to treat Parkinson's disease symptoms in conjunction with carbidopa-levodopa therapy. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered through oral, injection, and transdermal that are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The antiparkinson drugs market research report is one of a series of new reports from The Business Research Company that provides anti-Parkinson drugs market statistics, including anti-Parkinson drugs industry global market size, regional shares, competitors with an antiparkinson drugs market share, detailed anti-Parkinson drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-Parkinson drugs industry. This antiparkinson drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global anti-parkinson drugs market size will grow from $9.64 billion in 2022 to $10.23 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anti-parkinson drugs market size is expected to grow to $12.37 billion in 2027 at a CAGR of 4.9%.

The increasing geriatric population and surging cases of Parkinson's disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 cases of Parkinson's disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60. For instance, in June 2020, according to a study by the United Nations, the total number of people age 80 and above is expected to increase from 143 million in 2019 to over 426 million in 2050. Also, in February 2020, Harvard University, a US-based academic university specializing in teaching, learning, and research, will announce that, according to the Parkinson's Foundation, there are more than 10 million people living with Parkinson's disease globally, and this year, there will be close to one million cases in the United States. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease are therefore driving market growth.

Increased government and corporate investment in Parkinson's disease drug R&D is a major trend in the anti-Parkinson drugs market. For instance, in August 2022, the Parkinson’s Foundation, a US-based national organization that provides funding for research and educational resources, will make a $5.7 million investment in 33 projects to speed up cutting-edge research on Parkinson's disease (PD). Through research grants, the Foundation helps scientists carry out creative studies on numerous PD-related topics in an effort to develop novel therapies, treatments, and ultimately a cure for the 10 million people who suffer from this crippling neurological condition worldwide. Hence, increasing investments in Parkinson’s drug development are expected to drive the market for anti-Parkinson's drugs.

The high cost of Parkinson’s disease treatment is anticipated to limit the growth of the anti-Parkinson's drug market over the forecast period. According to the Michael J. Fox Foundation for Parkinson’s Research’s statistics, the economic burden of Parkinson’s disease on patients, families, and the federal government is increasing. In the United States, the overall cost of Parkinson’s disease to individuals, families, and government is $51.9 billion annually, with $25.4 billion on direct medical costs (including hospitalization and medication). Thus, the high cost of Parkinson's disease treatment is expected to impact the anti-Parkinson drugs market.

Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, paid $1.04 billion for Prevail Therapeutics Inc. in December 2020. Through this acquisition, Prevail's portfolio of clinical-stage and preclinical neuroscience assets will serve as the program's foundation, and the acquisition will introduce a new approach to Lilly's drug discovery and development processes. This will allow Lilly to expand its research efforts, launch a gene therapy program, and increase the drug development and commercialization capabilities of Lilly in the field of neurological disorders. Prevail Therapeutics Inc. is a US-based biotechnology company pioneering in the discovery and development of gene therapies for patients with Parkinson's disease and other neurodegenerative disorders.

Major players in the anti-Parkinson drugs market are GlaxoSmithKline PLC., Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc., Sun Pharma, Wockhardt, Dr. Reddy’s, Intas, US WorldMeds, Zydus Cadila, Cipla, Strides, 1 A Pharma, Upsher-Smith, Lundbeck, Vertical Pharmaceuticals, LLC., Zambon Pharmaceuticals, and M Somerset Pharmaceuticals Inc., and Wockhardt.

North America was the largest region in the anti-Parkinson drugs market in 2022. Middle East is expected to be the fastest-growing region in the global anti-parkinson drugs market during the forecast period. The regions covered in the global anti-Parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the anti-Parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The global anti-parkinson drugs market is segmented -

1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-Inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

    Table Of Contents

    1. Executive Summary

    2. Anti-Parkinson Drugs Market Characteristics

    3. Anti-Parkinson Drugs Market Trends And Strategies

    4. Anti-Parkinson Drugs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Anti-Parkinson Drugs Market

    4.2 Ukraine-Russia War Impact On Anti-Parkinson Drugs Market

    4.3 Impact Of High Inflation On Anti-Parkinson Drugs Market

    5. Anti-Parkinson Drugs Market Size And Growth

    5.1. Global Anti-Parkinson Drugs Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Anti-Parkinson Drugs Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Anti-Parkinson Drugs Market Segmentation

    6.1. Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Levodopa/Carbidopa

    Dopamine Receptor Agonists

    Monoamine Oxidase Type B (MAO-B) Inhibitors

    Catechol-O-Methyltransferase (COMT)-inhibitors

    Anticholinergics

    Other Drugs

    6.2. Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oral

    Injection

    Transdermal

    6.3. Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacies

    Retailer Pharmacies

    Online Pharmacies

    7. Anti-Parkinson Drugs Market Regional And Country Analysis

    7.1. Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Anti-Parkinson Drugs Market

    8.1. Asia-Pacific Anti-Parkinson Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Anti-Parkinson Drugs Market

    9.1. China Anti-Parkinson Drugs Market Overview

    9.2. China Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Anti-Parkinson Drugs Market

    10.1. India Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Anti-Parkinson Drugs Market

    11.1. Japan Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Anti-Parkinson Drugs Market

    12.1. Australia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Anti-Parkinson Drugs Market

    13.1. Indonesia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Anti-Parkinson Drugs Market

    14.1. South Korea Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Anti-Parkinson Drugs Market

    15.1. Western Europe Anti-Parkinson Drugs Market Overview

    15.2. Western Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Anti-Parkinson Drugs Market

    16.1. UK Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Anti-Parkinson Drugs Market

    17.1. Germany Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Anti-Parkinson Drugs Market

    18.4. France Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Anti-Parkinson Drugs Market

    19.1. Eastern Europe Anti-Parkinson Drugs Market Overview

    19.2. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Anti-Parkinson Drugs Market

    20.1. Russia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Anti-Parkinson Drugs Market

    21.1. North America Anti-Parkinson Drugs Market Overview

    21.2. North America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Anti-Parkinson Drugs Market

    22.1. USA Anti-Parkinson Drugs Market Overview

    22.2. USA Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Anti-Parkinson Drugs Market

    23.1. South America Anti-Parkinson Drugs Market Overview

    23.2. South America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Anti-Parkinson Drugs Market

    24.1. Brazil Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Anti-Parkinson Drugs Market

    25.1. Middle East Anti-Parkinson Drugs Market Overview

    25.2. Middle East Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Anti-Parkinson Drugs Market

    26.1. Africa Anti-Parkinson Drugs Market Overview

    26.2. Africa Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles

    27.1. Anti-Parkinson Drugs Market Competitive Landscape

    27.2. Anti-Parkinson Drugs Market Company Profiles

    27.2.1. GlaxoSmithKline plc

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Pfizer

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Merck

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Novartis

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Roche

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Anti-Parkinson Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market

    30. Anti-Parkinson Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: GlaxoSmithKline plc Financial Performance
  • Table 47: Pfizer Financial Performance
  • Table 48: Merck Financial Performance
  • Table 49: Novartis Financial Performance
  • Table 50: Roche Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: GlaxoSmithKline plc Financial Performance
  • Figure 47: Pfizer Financial Performance
  • Figure 48: Merck Financial Performance
  • Figure 49: Novartis Financial Performance
  • Figure 50: Roche Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report